Elosulfase alfa clinical trials
Also written BMN 110 and recombinant human N-acetylgalactosamine-6-sulfatase.
How each study uses elosulfase alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 14 Feb 2014 · VIMIZIM · BLA 125460 (FDA, Drugs@FDA)
- European Union
- 27 Apr 2014 · Vimizim · EMEA/H/C/002779 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2011 (2)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses elosulfase alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- BMN 110 Phase 3B in Australian PatientsCompletedPhase 3BioMarin PharmaceuticalNCT01966029Written as BMN 110
- Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome)CompletedPhase 2BioMarin PharmaceuticalNCT01515956Written as BMN 110
- Safety and Exercise Study of Two Doses of BMN 110 for Morquio A SyndromeTerminatedPhase 2BioMarin PharmaceuticalNCT01609062Written as BMN 110
- Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited AmbulationTerminatedPhase 2BioMarin PharmaceuticalNCT01697319Written as BMN 110
- A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)TerminatedPhase 1/2BioMarin PharmaceuticalNCT01242111Written as BMN 110
- A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)CompletedPhase 3BioMarin PharmaceuticalNCT01275066Written as BMN 110 Weekly
- A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVACompletedPhase 1/2BioMarin PharmaceuticalNCT00884949Written as BMN 110
Given beside what is tested · 2 — elosulfase alfa is usual care or a partner of the new treatment
Codes
What other systems call elosulfase alfa · ClinicalTrials.gg INT003942
- UNII (FDA) ODJ69JZG85ELOSULFASE ALFAConfirmed FDA, NLM, Wikidata
- RxNorm 1489914Confirmed FDA, Wikidata
- Wikidata Q21011232elosulfase alfaConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174795Elosulfase AlfaOne source FDA
- DrugBank DB09051One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | ODJ69JZG85 | ELOSULFASE ALFA | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1489914 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21011232 | elosulfase alfa | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174795 | Elosulfase Alfa | One source FDA |
| DrugBank | DB09051 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.